My MO and I have just decided to try the methodology reported in the study titled:
"Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC)".
Here is a link to the study:
ascopubs.org/doi/abs/10.120...
My prostate cancer details are as follows:
Prostate cancer, stage IIA, T1c N0 M0, Gleason score 7, now with metastasis to bones. (2 small spots on left hip)
My medication history is:
1/26/2015 – Focal Laser Ablation (FLA) PSA 4.9
10/7/2019 – repeat FLA PSA 16
6/8/2020 FLA 32
6/24/2020 Axumin Pet/CT scan
6/26/2020 Bone Scan Whole Body
7/14/2020 ADT Started – Firmagon, monthly
8/5/2020 Dexa Scan
8/11/2020 Zytiga -250 mg, prednisone 5mg daily continuing until now
9/1/2020 SpaceOAR Insertion
9/8/2020 – Xgeva – 120 mg - every 12 weeks
9/16/2020 – 10/13/2020 – radiation
10/27/2020 PSA <0.04 – continuing until now
10/27/2020 testosterone level - <7.0 continuing to present
7/12/2021 cancel Firmagon
7/13/2021 – Orgovyx daily until now
There was a discussion that included this subject area recently. Here is a link to it:
healthunlocked.com/advanced...
Read the replies.
I am interested in folks opinions on this methodology.
Note that I am still castrate sensitive.